Work out the cost

Medicare has different routes for different uses.

Medicare is not a single yes-or-no answer here. The reason for the prescription, the form of the medicine and the plan all matter.

Myth to test

Does Medicare never help with medicine used for weight?

Short answer

As of September 2026, a temporary Medicare GLP-1 Bridge offers certain medicines for weight treatment to eligible people at $50 per monthly supply.

Separate the temporary program from the drug benefit

Ordinary Part D, Medicare's drug benefit, still excludes medicine used only for weight loss.

Tirzepatide (Mounjaro) for type 2 diabetes can be eligible through Part D.
Tirzepatide (Zepbound) can also be eligible for moderate to severe sleep apnea, where breathing pauses during sleep, in adults with obesity.
Being eligible for Part D still leaves the plan's own medicine list and approval rules to check.
The September 2026 terms give the Bridge a start date of July 1, 2026, and an end date of December 31, 2027.

Under the September 2026 rules, Bridge applicants must be at least 18; the weight and health checks use the time treatment began.

BMI combines height and weight into a number; ask your care provider what yours was when treatment began.
At 35 or above, BMI meets the Bridge's weight requirement without any of the additional health conditions listed below.
For BMI at 30 or above, you also need one of these: a specified form of heart failure, uncontrolled high blood pressure, or kidney disease classed as stage 3a or beyond.
The heart condition must be recorded as heart failure with preserved ejection fraction; ask whether that is the kind in your record.
To meet this rule, blood pressure must stay high despite two medicines for blood pressure: either a top reading greater than 140 or a bottom reading greater than 90.
For BMI at 27 or above, the added health requirement can be met by peripheral artery disease with symptoms, pre-diabetes, or a history of heart attack or stroke.
Pre-diabetes means raised blood sugar short of diabetes; peripheral artery disease affects blood vessels in the arms or legs.
Use the diagnosis names in your records; ask which of these checks you meet.

Type 2 diabetes is excluded from the Bridge, as is sleep apnea that is moderate to severe, because those uses may qualify under ordinary Part D.

MASH is another reason for exclusion if it involves moderate to advanced liver scarring without cirrhosis, which means the most severe scarring.
MASH is the name of a liver illness involving fat and inflammation, or swelling; ask whether your record names that exact condition and scarring level.
An ordinary fatty-liver diagnosis alone does not establish that exclusion.
You must have either a separate Part D plan for medicines or a Medicare Advantage plan providing coordinated care with drug coverage.
Have the plan confirm which type it is; the name on your card can leave that unclear.
A GLP-1 prescription paid through Part D earlier in 2026 rules out your use of the Bridge for 2026.
The September rules do not yet say how earlier prescriptions will affect eligibility in 2027.
A prescription alone is insufficient for the Bridge: you also need prior authorization, its approval step, and a continuing plan covering food and physical activity.

For tirzepatide, the Bridge includes Zepbound's KwikPen, a medicine pen, rather than single-dose pens or vials, which are small bottles.

You pay $50 each month through the Bridge, but those payments do not go toward Part D's yearly limit on your spending.
Even after you reach Part D's yearly limit, you still owe the Bridge payment of $50 each month.
Part D assistance for people on low incomes leaves the Bridge payment unchanged.
Check with both your prescriber and your plan: which route fits your illness and the precise pen or bottle proposed?